Customers

ScienceCloud addresses collaboration challenges for different types of industries:


Pharmaceutical

The pharmaceutical industry is rapidly restructuring its discovery business to meet the needs of increased externalized research involving networks of third-party collaborators and contract research organizations (CROs). How do sponsoring pharmaceutical organizations ensure real-time collaboration with partners? How do they manage project IP in a secure but neutral place where contractual ownership is clear? How do they spin collaborators up and down as fast as their partner networks change? How do they enforce consistent business rules for results submission by network partners?

Biotechnology

Biotechnology companies are also relying more and more on external partners including pharmaceutical companies and CROs to conduct key parts of their discovery process and bring new drugs to market.  This means biotechs are facing the same challenges as pharmaceutical organizations in supporting real-time collaboration, managing project IP and enforcing business rules in rapidly changing, global partner networks. Traditional on-premises software infrastructure is no longer suitable in this new reality, and existing file-sharing solutions do not meet the needs of externalized biotech research.

Contract Research Organizations (CROs)

As pharmaceutical companies and biotechs increasingly rely on CROs for key aspects of the discovery process, CROs need to offer a higher level service to their customers to maintain a competitive advantage. How do CROs receive critical data, work requests and processes from their sponsors and other network participants? How do they return results back to their sponsor networks? Most importantly, how do they comply (and show that they have complied) with all documentation requirements, as well as the quality and presentation of results?

ScienceCloud helps pharma/biotech companies and CROs operate more efficiently while achieving the cost savings and accelerated innovation promised by today’s fundamental shift to an increasingly externalized life sciences research environment.